GH Research (GHRS) Other Operating Expenses (2022 - 2023)
GH Research (GHRS) posted quarterly Other Operating Expenses of -$518000.0 for Q1 2023, down 123.09% year-over-year from $2.2 million in Q1 2022, and down 123.09% quarter-over-quarter from $2.2 million in Q1 2022.
GH Research (GHRS) Other Operating Expenses (2022 - 2023) Analysis & Trends
GH Research's Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$518000.0 for Q1 2023.
- In Q1 2023, Other Operating Expenses fell 123.09% year-over-year to -$518000.0; the TTM figure through Dec 2023 stood at -$518000.0 (down 123.09% YoY), while the FY2025 annual figure was $121.1 million, up 20.74% from the prior year.
- Other Operating Expenses for Q1 2023 stood at -$518000.0, down from $2.2 million in the prior quarter.
- The five-year high for Other Operating Expenses was $2.2 million in Q1 2022, with the low at -$518000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -518,000.00 |
| Mar 31, 2022 | 2.24 Mn |